NCT05078931 2025-07-30A Study to Evaluate Pembrolizumab Plus Lenvatinib in PD-L1 Positive TKI Resistant NSCLC PatientsShanghai Chest HospitalPhase 2 Active not recruiting35 enrolled
NCT04164745 2019-11-15Efficacy and Safety Study of Anlotinib With Pembrolizumab in Adults With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Treatment-naïve Non-small Cell Lung CancerPeking Union Medical College HospitalPhase 2 Unknown49 enrolled